- ProMIS Neurosciences (PMN) will begin trading on Nasdaq under the symbol PMN on July 8
- Common shares of ProMIS Neurosciences will continue to trade on the Toronto Stock Exchange (TSX) under its current symbol
- The common shares of the company will cease to be quoted on the OTCQB
- ProMIS Neurosciences Inc. is a development-stage biotechnology company
- ProMIS Neurosciences Inc. opened trading at $8.22 per share
ProMIS Neurosciences (PMN) has received approval from The Nasdaq Capital Market LLC to list its common shares on Nasdaq.
Effective July 8, the company’s common shares will begin trading on Nasdaq under the symbol PMN.
Common shares of ProMIS Neurosciences will continue to trade on the Toronto Stock Exchange (TSX) under its current symbol.
The company’s common shares will cease to be quoted on the OTCQB.
“The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly traded company,” stated Eugene Williams, Chairman and CEO of ProMIS.
“We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value,” he added.
ProMIS Neurosciences Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
ProMIS Neurosciences Inc. opened trading at $8.22 per share.
